Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Dapagliflozin improves albuminuria in patients with high cardiorenal risk

The Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Dapagliflozin, improves renal specific outcomes, especially urinary albumin-to-creatinine ratio (UACR) and may prevent diabetic kidney disease, as a per a study in ‘Diabetes Care ‘. The study was conducted in 17,160 patients to measure the change in baseline UACR and cardio-renal outcomes to the drug dapagliflozin at 6 months, 12 months, and yearly thereafter. All participants included in this study had type-2 diabetes, creatine clearance of >60mL/min and cardiovascular risk factors.

The following were the key findings:

  • UACR improved from baseline to 4.0 years with dapagliflozin, compared with placebo across all UACR and estimated glomerular filtration rate (eGFR) categories.
  • Cardiorenal outcome was improved with dapagliflozin in patients from subgroups of UACR ≥30 mg/g compared to placebo.

This study concludes that dapagliflozin demonstrable beneficial effect on UACR and renal-specific outcome across baseline UACR categories, including patients with normal albumin excretion. Furthermore, the results imply that dapagliflozin may also play a role in the prevention of diabetic kidney disease.


1. Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP. Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021 Aug;44(8):1805-1815. Accessed on 30-10-2021.